ImmunityBio, Inc.IBRXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel chemotherapy-free and lymphodepletion-free combination immunotherapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL), including Waldenström's Macroglobulinemia. The outpatient study evaluates ImmunityBio's novel, off-the-shelf CD19-targeted high-affinity natural killer (NK) cell therapy.

defenseworld.net

Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ: IBRX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Insider and Institutional Ownership 8.6% of ImmunityBio shares are

prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

fool.com

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

Expand NASDAQ: IBRX ImmunityBio Today's Change (-3.72%) $-0.24 Current Price $6.21 Key Data Points Market Cap $6.4B Day's Range $6.16 - $6.75 52wk Range $1.83 - $8.28 Volume 37M Avg Vol 23M Gross Margin 80.41% ImmunityBio (IBRX 3.72%), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path.

defenseworld.net

ImmunityBio (NASDAQ:IBRX) Director Sells $187,750.00 in Stock

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) Director Christobel Selecky sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The sale was disclosed in a filing with the Securities and Exchange Commission,

fool.com

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

Expand NASDAQ: IBRX ImmunityBio Today's Change (-12.13%) $-0.89 Current Price $6.45 Key Data Points Market Cap $7.2B Day's Range $6.43 - $7.88 52wk Range $1.83 - $8.28 Volume 75M Avg Vol 22M Gross Margin 80.41% ImmunityBio (IBRX 12.13%), an immunity-focused biotech, closed Friday's session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month.

businesswire.com

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence, today announced updated Phase 2 clinical results from QUILT 3.078 (NCT06061809), evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progressive glioblastoma (GBM), as well as patients treated under single-patient INDs (spINDs) across first- t.

fool.com

Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses

Expand NASDAQ: IBRX ImmunityBio Today's Change (6.79%) $0.44 Current Price $6.92 Key Data Points Market Cap $6.4B Day's Range $5.71 - $7.10 52wk Range $1.83 - $7.98 Volume 96M Avg Vol 19M Gross Margin 80.41% ImmunityBio (IBRX +6.79%), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do after the company's share price tripled in just three weeks this year.

zacks.com

ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission

IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.

fool.com

Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer

Expand NASDAQ: IBRX ImmunityBio Today's Change (17.39%) $0.96 Current Price $6.48 Key Data Points Market Cap $5.4B Day's Range $6.08 - $7.98 52wk Range $1.83 - $7.98 Volume 210M Avg Vol 16M Gross Margin 80.41% ImmunityBio (IBRX +17.39%), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label expansion in bladder cancer, and investors are watching next steps on the planned data resubmission path.

benzinga.com

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

ImmunityBio Inc. (NASDAQ: IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related to its supplemental biologics license application for Anktiva in papillary non-muscle invasive bladder cancer (NMIBC).

gurufocus.com

Wealth Management Associates, Inc. Buys 19,000 Shares of ImmunityBio Inc (IBRX)

Summary Wealth Management Associates, Inc. initiated a new position in ImmunityBio Inc(IBRX), purchasing 19,000 shares valued at approximately $37,620

benzinga.com

Top 3 Health Care Stocks You May Want To Dump In January

As of Jan. 20, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

businesswire.com

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company's supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors. The Company presented an overview of the clinical status of i.

ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results

zacks.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance